Stockscreener 앱 받기
57.09
1.53%
0.86
시간 외 거래:
57.09
전일 마감가:
$56.23
열려 있는:
$56.01
하루 거래량:
2.48M
Relative Volume:
0.69
시가총액:
$25.31B
수익:
$2.44B
순이익/손실:
$1.36B
주가수익비율:
29.90
EPS:
1.9093
순현금흐름:
$574.14M
1주 성능:
+6.57%
1개월 성능:
+2.39%
6개월 성능:
+46.08%
1년 성능:
+59.16%
1일 변동 폭
$55.65
$57.17
1주일 범위
$53.31
$57.17
52주 변동 폭
$34.08
$57.17
로열티 파마 Stock (RPRX) Company Profile
명칭
Royalty Pharma Plc
전화
(212) 883-0200
주소
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
57.09 | 24.93B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
499.65 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
631.81 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
912.46 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
192.62 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.52 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
로열티 파마 Stock (RPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 업그레이드 | UBS | Neutral → Buy |
| 2025-09-30 | 개시 | Goldman | Buy |
| 2025-05-16 | 개시 | Morgan Stanley | Overweight |
| 2024-06-03 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-06-14 | 재개 | UBS | Buy |
| 2022-05-13 | 개시 | Scotiabank | Sector Outperform |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2021-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-30 | 개시 | Tigress Financial | Buy |
| 2020-11-09 | 업그레이드 | UBS | Neutral → Buy |
| 2020-07-14 | 개시 | Evercore ISI | In-line |
| 2020-07-13 | 개시 | BofA Securities | Buy |
| 2020-07-13 | 개시 | Citigroup | Neutral |
| 2020-07-13 | 개시 | Cowen | Outperform |
| 2020-07-13 | 개시 | Goldman | Neutral |
| 2020-07-13 | 개시 | JP Morgan | Neutral |
| 2020-07-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 개시 | SunTrust | Buy |
| 2020-07-13 | 개시 | UBS | Neutral |
모두보기
로열티 파마 주식(RPRX)의 최신 뉴스
Royalty Pharma (NASDAQ:RPRX) Hits New 12-Month HighTime to Buy? - MarketBeat
Royalty Pharma stock hits all-time high at 56.57 USD - Investing.com
Royalty Pharma stock hits all-time high at 56.57 USD By Investing.com - Investing.com Canada
Royalty Pharma, plc (RPRX) Rallied on Earnings Beat - Insider Monkey
Rockefeller Capital Management L.P. Purchases 81,747 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Does Royalty Pharma’s (RPRX) Index Upgrade Signal Deeper Defensive Strength In Its Business Model? - simplywall.st
Enterprise value to revenue forward of Royalty Pharma plc – NASDAQ:RPRX - TradingView
Trading Systems Reacting to (RPRX) Volatility - Stock Traders Daily
Royalty Pharma PLC $RPRX Shares Sold by Goodman Advisory Group LLC - MarketBeat
Enterprise value to EBITDA forward of Royalty Pharma plc – NASDAQ:RPRX - TradingView
Price to earnings forward of Royalty Pharma plc – NASDAQ:RPRX - TradingView
Enterprise value to EBITDA forward of Royalty Pharma Plc Class A – SWB:RPD - TradingView
Price to sales forward of Royalty Pharma plc – NASDAQ:RPRX - TradingView
Enterprise value to revenue forward of Royalty Pharma Plc Class A – SWB:RPD - TradingView
Price to sales forward of Royalty Pharma Plc Class A – SWB:RPD - TradingView
Price to earnings forward of Royalty Pharma Plc Class A – SWB:RPD - TradingView
Barton Investment Management Makes New Investment in Royalty Pharma PLC $RPRX - MarketBeat
Insider Sell Alert: Marshall Urist Sells Shares of Royalty Pharm - GuruFocus
Form 4 Royalty Pharma Plc For: 25 June By Investing.com - Investing.com Nigeria
Royalty Pharma EVP Hite sells $8.16m in shares - Investing.com UK
Royalty Pharma EVP Hite sells $8.16m in shares By Investing.com - Investing.com Australia
Royalty Pharma (NASDAQ:RPRX) EVP Sells 9,098 Shares - MarketBeat
Royalty Pharma (RPRX) EVP Marshall Urist sells 9,098 shares under 10b5-1 plan - Stock Titan
Executive-linked fund sells 150K Royalty Pharma (RPRX) shares under 10b5-1 plan - Stock Titan
Royalty Pharma Plc Class A Actuals & Estimates (NASDAQ:RPRX) - TradingView
RPRX Forecast — Price Target — Prediction for 2027 - TradingView
Form 144 Royalty Pharma plc For: 24 June By Investing.com - Investing.com Australia
Marshall Urist sells shares at Royalty Pharma plc (NASDAQ: RPRX) - Stock Titan
Royalty Pharma - Forbes
Kirr Marbach & Co. LLC IN Acquires Shares of 237,895 Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (RPRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Form 144 Royalty Pharma PLC For: 23 June By Investing.com - Investing.com South Africa
[144] Royalty Pharma plc SEC Filing - Stock Titan
Look Beyond Market Euphoria After 3 FCF ETFs Rebalanced - ETF Database
Royalty Pharma plc (RPRX) Stock Analysis: Exploring an 11.88% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Three “Forever Stocks” for the AI Age - InvestorPlace
River Road Asset Management LLC Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
ROYALTY PHARMA PLC- CL A (RPRX) Stock Chart - ChartMill
Don't Ignore The Insider Selling In Royalty Pharma - simplywall.st
Royalty Pharma PLC (RPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Royalty Pharma PLC (RPRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Royalty Pharma PLC (RPRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
How Royalty Pharma Plc (RPRX) Affects Rotational Strategy Timing - Stock Traders Daily
Royalty Pharma PLC (RPRX) Institutional Confidence - TradingKey
Royalty Pharma PLC (RPRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Royalty Pharma PLC (RPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Royalty Pharma PLC (RPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Royalty Pharma PLC (RPRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Dorsey Asset Management LLC Trims Stake in Royalty Pharma PLC $RPRX - MarketBeat
Delta Global Management LP Acquires Shares of 44,314 Royalty Pharma PLC $RPRX - MarketBeat
로열티 파마 (RPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.94%
자본화:
|
볼륨(24시간):